Ally Bridge Group NY LLC acquired a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 348,000 shares of the company's stock, valued at approximately $2,593,000. EyePoint Pharmaceuticals comprises about 2.2% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 20th biggest holding. Ally Bridge Group NY LLC owned about 0.51% of EyePoint Pharmaceuticals at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. RA Capital Management L.P. acquired a new position in EyePoint Pharmaceuticals during the 4th quarter valued at about $23,705,000. One68 Global Capital LLC purchased a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter worth about $192,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter worth about $91,000. TCG Crossover Management LLC boosted its holdings in EyePoint Pharmaceuticals by 287.3% during the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock valued at $26,614,000 after acquiring an additional 2,650,000 shares during the period. Finally, Nantahala Capital Management LLC bought a new position in EyePoint Pharmaceuticals during the fourth quarter worth $4,470,000. Institutional investors own 99.41% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Citigroup assumed coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating and a $33.00 target price on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $26.63.
Get Our Latest Stock Analysis on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Price Performance
NASDAQ:EYPT traded down $0.08 during mid-day trading on Wednesday, reaching $6.17. The stock had a trading volume of 464,705 shares, compared to its average volume of 840,608. EyePoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $13.99. The stock has a market capitalization of $424.77 million, a PE ratio of -3.11 and a beta of 1.58. The stock has a 50-day simple moving average of $6.02 and a two-hundred day simple moving average of $7.59.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.65). The firm had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. Equities analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.
About EyePoint Pharmaceuticals
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Read More

Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.